Todas as matérias desta seção, das mais recentes às mais antigas — página 237 de 371.
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
Canton Strategic Holdings (NASDAQ:CNTN) reported its full-year 2025 financial results on Tuesday, March 31, 2026, marking its first complete fiscal year since pivoting to a dedicated digital asset and blockchain infrastructure strategy.
SPAR Group (NASDAQ:SGRP) issued optimistic financial guidance for fiscal year 2026 on Tuesday, March 31, 2026, signaling a major turn toward higher profitability and operational efficiency.
Scholar Rock (NASDAQ:SRRK) announced on Tuesday, March 31, 2026, that it has officially resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab.
SCYNEXIS (NASDAQ:SCYX) announced a transformative strategic shift on Tuesday, March 31, 2026, transitioning its core focus toward rare kidney diseases through a significant asset acquisition and a major equity financing.
AIRO Group Holdings (NASDAQ:AIRO) announced financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, highlighting significant double-digit revenue growth and a return to break-even profitability.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported robust financial and operational results for the full year 2025 on Tuesday, March 31, 2026, headlined by a 65% surge in net product revenue.
MiNK Therapeutics (NASDAQ:INKT) reported its fourth-quarter and full-year 2025 financial results on Tuesday, detailing a well-capitalized path toward several major clinical readouts in the coming year.
Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.
BOS (NASDAQ:BOSC) reported record-breaking financial results for the full year 2025 on Tuesday, characterized by significant double-digit growth across all key profitability metrics.
Soligenix (NASDAQ:SNGX) reported financial results for the full year ended December 31, 2025, on March 31, 2026, emphasizing a clear pathway toward critical late-stage clinical data readouts.
Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.
Eli Lilly and Company (NYSE:LLY) announced a definitive agreement on Tuesday to acquire Centessa Pharmaceuticals, marking a significant strategic entry into the sleep medicine market.
Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
TD SYNNEX (NYSE:SNX) reported exceptional financial results for the fiscal first quarter ended February 28, 2026, significantly outperforming its previous guidance across all major metrics.
J.Jill (NYSE:JILL) announced financial results for the fourth quarter and fiscal year ended January 31, 2026, on Tuesday, reporting a 3.1% decrease in quarterly net sales to $138.4 million.
McCormick & Company (NYSE:MKC) announced robust first-quarter fiscal 2026 results on Tuesday, characterized by a significant double-digit increase in net sales following the successful integration of its major regional acquisition.
TOYO (NASDAQ:TOYO) reported a transformative fiscal year 2025 on Tuesday, characterized by a 142% surge in annual revenue as the company successfully scaled its international manufacturing footprint.
Jiayin Group (NASDAQ:JFIN) reported unaudited fourth-quarter and full-year 2025 financial results on Tuesday, detailing a strategic pivot toward asset quality as the Chinese fintech sector undergoes a significant regulatory-driven transition.
LENSAR (NASDAQ:LNSR) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, highlighted by the continued commercial momentum of its ALLY Adaptive Cataract Treatment System.
iHuman (NYSE:IH) reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, revealing a cooling in top-line growth even as the company remains profitable and committed to shareholder returns.
Super Hi (NASDAQ:HDL) reported unaudited full-year 2025 financial results on Tuesday, characterized by a nearly 70% surge in annual profit and double-digit revenue growth in the final quarter.
Sound Group (NASDAQ:SOGP) reported a significant financial turnaround for the fiscal year ended December 31, 2025, characterized by robust revenue growth and a return to bottom-line profitability.
T1 Energy (NYSE:TE) reported record operational performance for the fourth quarter and full-year 2025, driven by a surge in manufacturing throughput and the successful execution of several strategic capital initiatives.
